摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(Benzyloxy)pyrimidin-2(1H)-one | 924311-91-1

中文名称
——
中文别名
——
英文名称
4-(Benzyloxy)pyrimidin-2(1H)-one
英文别名
6-phenylmethoxy-1H-pyrimidin-2-one
4-(Benzyloxy)pyrimidin-2(1H)-one化学式
CAS
924311-91-1
化学式
C11H10N2O2
mdl
——
分子量
202.213
InChiKey
TVEJATSLQWJEJB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.21±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    50.7
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • Hydroxypyridonate and hydroxypyrimidinone chelating agents
    申请人:Raymond N. Kenneth
    公开号:US20050008570A1
    公开(公告)日:2005-01-13
    The present invention provides hydroxypyridinone and hydroxypyrimidone chelating agents. Also provides are Gd(III) complexes of these agents, which are useful as contrast enhancing agents for magnetic resonance imaging. The invention also provides methods of preparing the compounds of the invention, as well as methods of using the compounds in magnetic resonance imaging applications.
    本发明提供了羟基吡啶酮和羟基嘧啶酮螯合剂。还提供了这些剂的Gd(III)配合物,这些配合物可用作磁共振成像的造影增强剂。该发明还提供了制备本发明化合物的方法,以及在磁共振成像应用中使用这些化合物的方法。
  • Pyridone Compounds
    申请人:Ando Makoto
    公开号:US20100216758A1
    公开(公告)日:2010-08-26
    An active ingredient is a compound represented by the general formula [I]: [wherein R 1 and R 2 represent a lower alkyl group, a C 3-6 cycloalkyl group or the like, X 1 and X 2 represent methine, an Ar—Y 1 —Y 2 —Y 3 -substituted methine or the like, however either of them is an Ar—Y 1 —Y 2 —Y 3 -substituted methine, X 3 to X 8 represent methine, —N— or the like, Y 1 and Y 3 represent a single bond, —O— or the like, Y 2 represent a single bond, a lower alkylene group or the like, W represent —(O)—(CH 2 )n-(O)— or the like, n represents an integer of 1 to 4, L and Z 2 represent a single bond or a methylene group, Z 1 represents a single bond, a C 1-4 alkylene group or the like, and Ar represents an aromatic carbocyclic group or the like]. The compound acts as a melanin-concentrating hormone receptor antagonist and useful as a therapeutic agent for obesity or the like.
    活性成分是由通式[I]表示的化合物:[其中R1和R2表示低级烷基、C3-6环烷基或类似物,X1和X2表示亚甲基、Ar—Y1—Y2—Y3取代亚甲基或类似物,但其中任一种为Ar—Y1—Y2—Y3取代亚甲基,X3到X8表示亚甲基、—N—或类似物,Y1和Y3表示单键、—O—或类似物,Y2表示单键、低级烷基亚ethylene基或类似物,W表示—(O)—(CH2)n-(O)—或类似物,n表示1到4的整数,L和Z2表示单键或亚甲基,Z1表示单键、C1-4烷基亚ethylene基或类似物,Ar表示芳香族碳环基或类似物]。该化合物作为黑色素浓缩激素受体拮抗剂,可用作治疗肥胖症或类似疾病的治疗剂。
  • PYRIDONE COMPOUND
    申请人:BANYU PHARMACEUTICAL CO., LTD.
    公开号:EP1916239A1
    公开(公告)日:2008-04-30
    An active ingredient is a compound represented by the general formula [I]: [wherein R1 and R2 represent a lower alkyl group, a C3-6 cycloalkyl group or the like, X1 and X2 represent methine, an Ar-Y1-Y2-Y3-substituted methine or the like, however either of them is an Ar-Y1-Y2-Y3-substituted methine, X3 to X8 represent methine, -N- or the like, Y1 and Y3 represent a single bond, -O- or the like, Y2 represent a single bond, a lower alkylene group or the like, W represent -(O)-(CH2)n-(O)- or the like, n represents an integer of 1 to 4, L and Z2 represent a single bond or a methylene group, Z1 represents a single bond, a C1-4 alkylene group or the like, and Ar represents an aromatic carbocyclic group or the like]. The compound acts as a melanin-concentrating hormone receptor antagonist and useful as a therapeutic agent for obesity or the like.
    活性成分是由通式[I]表示的化合物: [其中 R1 和 R2 代表低级烷基、C3-6 环烷基或类似基团,X1 和 X2 代表甲烷、Ar-Y1-Y2-Y3 取代的甲烷或类似基团,但其中任一基团为 Ar-Y1-Y2-Y3 取代的甲烷,X3 至 X8 代表甲烷、-N- 或类似基团,Y1 和 Y3 代表单键、-O- 或类似基团、Y2 代表单键、低级亚烷基或类似基团,W 代表-(O)-(CH2)n-(O)-或类似基团,n 代表 1 至 4 的整数,L 和 Z2 代表单键或亚甲基,Z1 代表单键、C1-4 亚烷基或类似基团,Ar 代表芳香碳环基团或类似基团]。该化合物是一种黑色素浓缩激素受体拮抗剂,可用作肥胖症或类似疾病的治疗剂。
  • HYDROXYPYRIDONATE AND HYDROXYPYRIMIDINONE CHELATING AGENTS
    申请人:THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    公开号:EP1423399A2
    公开(公告)日:2004-06-02
  • EP1423399A4
    申请人:——
    公开号:EP1423399A4
    公开(公告)日:2008-05-07
查看更多